No writing assistance was utilized in the production of this manuscript. Ligand-mediated EGF receptor (EGFR) targeting of nanovehicles is an effective way for cancer cell-selective delivery of ...

Proto-oncogenes regulate cell growth; mutations convert them to oncogenes, leading to cancer by disrupting normal cell ...

ArriVent BioPharma is developing a treatment for non-small cell lung cancer. Click here to read more about AVBP stock and ...

Findings showed treatment with Rybrevant plus chemotherapy significantly reduced the risk of disease progression or death by 52% compared with chemotherapy.

Johnson & Johnson (JNJ) announced that the U.S. Food and Drug Administration approved RYBREVANT (amivantamab-vmjw) in combination ...

Approvals are coming fast and furious for Johnson & Johnson’s Rybrevant as it is lining up to challenge the dominance of ...

The Food and Drug Administration (FDA) has just approved the drug Kisqali (ribociclib) in combination with an aromatase ...

Black women in the US have a significantly higher risk of breast cancer mortality across all subtypes, with disparities ...

The epidermal growth factor receptor tyrosine kinase inhibitor aumolertinib demonstrated improved progression-free survival ...

Wednesday announced the receipt of Fast Track Designation from the FDA for ATR-04, a topical treatment targeting ...

The FDA approval of amivantamab-vmjw (Rybrevant) in combination with chemotherapy is the first targeted treatment to cut ...

Some patients with non-small cell lung cancer (NSCLC) have mutations in a gene called human epidermal growth factor receptor ...